You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.
Introducing our next-generation Xpert Xpress CoV-2/Flu/RSV plus test, designed to include a more robust three-gene detection of CoV-2 to enable virus variant detection and further mitigate the possible effects of viral mutations.
Enter the upcoming respiratory virus season with the confidence of a single test to detect and differentiate SARS-CoV-2, Flu A, Flu B, and RSV. The test can provide rapid on-demand detection of SARS-CoV-2 as soon as 25 minutes for positive results* and provide results for all four pathogens in just 36 minutes with less than a minute of hands-on time.
Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19. The test leverages the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted. The test can provide rapid detection of the current coronavirus SARS-CoV-2 in as soon as 30 minutes for positive results^ with less than a minute of hands-on time to prepare the sample.
9/14/21: Cepheid Receives Emergency Use Authorization for Xpert Xpress CoV-2/Flu/RSV plus
3/21/2020: Cepheid Receives Emergency Use Authorization from FDA for Rapid SARS-CoV-2 Test
3/22/20: HHS, DoD collaborate with Cepheid on rapid diagnostics to detect coronavirus infections
2/10/2020: Cepheid Announces Development of Test for New Coronavirus Strain (2019-nCoV)
Below is a list of common questions and answers for Cepheid’s SARS-CoV-2 tests.
For additional information please
For the upcoming respiratory season in the Northern Hemisphere, Cepheid has launched a test that provides rapid, accurate detection and differentiation of SARS-CoV-2, Flu A, Flu B, and RSV in as little as 36 minutes, while offering three gene targets for SARS-CoV-2 to enable detection of current and future variants of the SARS-CoV-2 virus. The test has been designed for broader coverage to mitigate the possible effects of viral genetic drift.
Cepheid’s tests are well suited for pandemic response. Many of our GeneXpert® Systems are in hospital labs and other near-patient settings. From the time a sample (such as a nasopharyngeal swab) is taken, a result can be obtained in less than an hour. We call this “sample to answer” and the samples can be loaded as they are received for true on-demand testing. It takes less than a minute to prepare the cartridge with the patient sample. The new Xpert Xpress CoV-2/Flu/RSV plus test can report a positive result for SARS-CoV-2 as soon as 25 minutes* after a test cartridge is loaded onto the system.
Click the green Request Information button at the top of this page to be connected with your local Cepheid Sales Representative.
The tests are designed to detect the SARS-CoV-2 strain of the coronavirus, the virus that causes COVID-19. Xpert Xpress CoV-2/Flu/RSV plus uses the E, N2, and RdRP genes to detect SARS-CoV-2, and also detects and differentiates Flu A, Flu B, and RSV.
Xpert Xpress CoV-2/Flu/RSV plus supports a variety of sample types including nasopharyngeal and anterior nasal swabs in UTM/VTM, saline, or eNAT. Additional information, including sample types for Cepheid’s other SARS-CoV-2 tests, can be found on the product resource page at www.cepheid.com/coronavirus-resources and in the package inserts.^
